The phrase "alter the affinity" is correct and usable in written English.
It can be used in contexts related to chemistry, biology, or any field discussing relationships or interactions between entities, such as molecules or individuals.
Example: "The researchers aimed to alter the affinity of the enzyme for its substrate to improve reaction efficiency."
Alternatives: "change the attraction" or "modify the binding affinity."
Thus, pharmacologic manipulation can alter the affinity of the chemotactic factor receptor on human PMN; this alteration is associated with a change in receptor function.
The results showed that the modification of the aptamer does not significantly alter the affinity of the aptamer for the antibiotic.
Furthermore, the cysteine at VL85 of ds-FV57 was mutated to serine to construct ds-FV57VL85Ser in order to avoid potential mis-formed disulfide bonds which would alter the affinity of the scFv.
Thus, the chemical modifications (the addition of a spacer, a chelator and Ga) did not alter the affinity of R824 to its target, i.e. the PS.
The affinity studies of our labelled conjugated peptide showed that the adding of a spacer and of a chelating group in the Peptide N-terminus side did not alter the affinity and binding of R824 to its target.
On the other hand, the E406A mutation did not significantly alter the affinity of the three inhibitors (Table 3).
Effectors include myosin II for inducing tension, calpain to cleave talin and other adhesion components, and phosphorylation events that alter the affinities of different adhesion components (8).
E1 enzymes reorganize the three-dimensional arrangement of their domains to generate the active site environments for chemically distinct reactions and to progressively alter the affinities for their sequential macromolecular substrates.
In vitro experiments also showed that artificial envelopment of Ad completely altered the affinity towards both human and murine red blood cells.
By altering the affinity of the receptor using pharmacological means one may be able to modify the biological activity of human PMNs.
This is likely to reflect a structural change in the DR molecule which alters the affinity of binding of the DRβ chain specific monoclonal antibody while the DRα chain specific mAb remains unaffected.
